Hacker News new | past | comments | ask | show | jobs | submit login

yes, but the phase 3 (efficacy) trial just barely crossed the threshold (if I remember correctly), mostly because the company wanted to use one stereoisomer because the other was not patentable (and this is the one that is less trippy)

https://slatestarcodex.com/2019/03/11/ketamine-now-by-prescr...




Guidelines | FAQ | Lists | API | Security | Legal | Apply to YC | Contact

Search: